stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Revenue
BridgeBio Pharma, Inc.'s revenue for fiscal 2025 was $502.1M, up 126.3% from $221.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $945.5M. Over the past ten years it has ranged from $8.2M (fiscal 2020) to $502.1M (fiscal 2025) — the current reading is the highest in ten years. BridgeBio Pharma, Inc. ranks 28th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $502.1M | 126.26% |
| FY2024 | $221.9M | 2,285.27% |
| FY2023 | $9.3M | (88.02%) |
| FY2022 | $77.6M | 11.38% |
| FY2021 | $69.7M | 745.14% |
| FY2020 | $8.2M | (79.66%) |
| FY2019 | $40.6M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $353.2M | 44.93% |
| Jun 2026 | $243.7M | 25.27% |
| Mar 2026 | $194.5M | 26.16% |
| Dec 2025 | $154.2M | 27.74% |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BMRN BioMarin Pharmaceutical Inc. compare | $3.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| HALO Halozyme Therapeutics, Inc. compare | $1.8B |
| TECH Bio-Techne Corp compare | $1.2B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. | $945.5M |
| KYMR Kymera Therapeutics, Inc. compare | $105.0M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BBIO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement